Navigation Links
ESTEVE Communicates its R&D Through a New Interactive Platform
Date:7/12/2012

BARCELONA, July 12, 2012 /PRNewswire/ --

This site is part of the  http://www.esteve.com  corporate web portal

  • ESTEVE's new website provides consise and updated information on its projects under development. Among these is the S1RA (Sigma-1 Receptor Antagonist), a new chemical entity, presently in Clinical Phase II, for treating several types of pain
  • In addition to defining the Company's main lines of research, this new website also discloses the Company's different and innovative models of collaboration

ESTEVE announces the launch of a new website (http://www.esteve.es/EsteveFront/IDI.do?lng=en) with the purpose of communicating the Company's R&D and the innovative models of collaboration currently implemented. Newly formatted and fully integrated in the http://www.esteve.com web portal, this site reinforces the commitment of ESTEVE to R&D with emphasis on a solid strategy to provide new therapeutic solutions for unmet medical needs in highly prevalent diseases of high social impact.

With its primary focus in analgesia, ESTEVE is developing innovative therapies for pain. Two projects are presently undergoing clinical development for the treatment of neuropathic pain and moderate to severe acute and chronic pain.

One of these projects involves S1RA, a highly selective Sigma-1 Receptor Antagonist that offers a new approach and a new mechanism of action in a field (neuropathic pain) strongly in need of novel, more effective and safer therapies.

The new website also describes the innovative partnering strategy in R&D as well as ESTEVE's network of excellence built through unique collaborative models. This network includes different types of alliances, from public-private partnerships -such as the HIVACAT program to develop an effective vaccine against HIV and the Sanfilippo project to develop a treatment for a rare childhood disease- to R&D consortiums such as Neogenius for pain research.

One of the key features of this site is its attractively designed interface for portfolio presentation, which includes the various ongoing R&D programs, i.e. in-house projects in analgesia, projects in collaboration with other centers or companies, and in-licensed projects.

With language and information customized for each audience, this new website provides specific information for scientists, healthcare providers, industry partners, patients and other stakeholders.

About ESTEVE

ESTEVE is a leading chemical-pharmaceutical group in Spain and has a strong international presence. Ever since its foundation in 1929, ESTEVE has been firmly committed to excellence and has been using its best efforts to promote health and improve people's quality of life.



'/>"/>
SOURCE ESTEVE
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BIRD - Israel-US Binational Industrial R&D Foundation to Invest $7.15 Million in Eight New Projects
2. picoSpin-45 Miniature NMR Spectrometer Wins R&D 100 Award
3. ORNL wins 9 R&D 100s, bringing total to 173
4. New life sciences R&D model based on real-time learning and data-sharing needed to sustain innovation
5. Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. Mandy Moore Campaigns for Clean Water, GreenBeanBuddy Encourages Mothers to Help Through the Use of Green Cleaning Products
8. Innovation Leaders from Across Industries will Convene to Share Best Practices and Breakthrough Successes at Open Innovation Leadership Summit
9. Nanodiamonds cut through dirt to bring back bling to low-temperature laundry
10. Soundbites Breaks Through at 47th AES Conference
11. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second time ... US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. ... US2020. , US2020’s mission is to change the trajectory of STEM education in ...
(Date:10/10/2017)... Oct. 10, 2017 International research firm Parks Associates ... speak at the TMA 2017 Annual Meeting , October 11 in ... the residential home security market and how smart safety and security products ... Parks Associates: Smart ... "The residential security market ...
Breaking Biology Technology:
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
Breaking Biology News(10 mins):